Recently CYFRA 21-1, a new tumour marker measuring a fragment of cytokeratin 19, was introduced (1,2) and proved to be suitable for the follow-up care and monitoring of the therapy of non-small cell lung carcinomas, especially squamous cell carcinomas of the lung (3, 4). Besides CYFRA 21-1, there are two other tumour markers available, called tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS), which also measure different cytokeratins in serum. In a retrospective study we investigated the clinical significance of these 3 cytokeratin markers in lung cancer compared with carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE). We investigated the sera of 50 healthy persons, 273 patients with various benign diseases and 218 patients with histologically proven lung cancer. In a first step the specificity versus benign diseases of the lung was established for all the markers, and was fixed at 95%. Then the single and combined sensitivities were calculated. CYFRA 21-1 proved to possess the highest sensitivity in lung cancer in general (61%), in non-small cell lung carcinomas (64%), in squamous cell carcinomas (79%), in adenocarcinomas (54%) and in large cell carcinomas (65%). In small cell lung carcinomas, neuron-specific enolase proved again to be the marker of first choice (55%). Combined determinations proved clearly increased sensitivity only for large cell carcinomas (CYFRA 21-1 + TPA: 77%) and for small cell lung carcinomas (CYFRA 21-1 + NSE: 62%). From our investigations it was evident that TPA detects at least partly the same substance as CYFRA 21-1 (the sensitivities compared with the markers TPS, CEA, SCC and NSE were rather high, but not as high as for CYFRA 21-1), whereas the TPS assay measures a completely different clinical chemical analyte (lowest number of true positive test results over the whole investigation). These findings correspond cleary to the very recent results of the comparison of CYFRA 21-1, TPA and TPS by immunoblotting (5).
Introduction
_ ,, , ^.r-r-,^ * ~ * Recently a new tumour marker, called CYFRA 21-1, In many industrialized countries, lung cancer is the was described for the detection of cytokeratin 19-inost common cancer in men and is climbing quickly fragments in serum (1, 2) . Cytokeratins and other toward the same incidence in women. Clinical chem-intermediate filaments of the cell like vimentin and ical methods for the support of adequate follow up desmin have become well known since the developcare and the control of efficiency of therapy are avail-ment of monoclonal antibodies in histopathology for able only for small cell lung carcinomas, and they the differentiation and classification of physiological consist of the determination of neuron specific enolase and pathological tissues (8, 9) . The expression of a (6, 7) .
single cytokeratin or a combination of certain cyto-keratins is typical for defined tissues, for example cytokeratin 7 and 8 in the epithelium of the trachea and urothelium. In contrast to cytokeratins themselves, fragments of intermediate filaments are soluble in serum and can therefore be detected and measured with the aid of monoclonal antibodies. Since cytokeratin 19 is particulary abundant in carcinoma of the lung (10, 11) , the assay CYFRA 21-1, combining two monoclonal antibodies directed specifically against this cytokeratin, was developed (1, 2).
According to our own investigations, (3, 4) and the results of a European multicentre study, CYFRA 21-1 shows a good specificity-sentitivity-profile in lung cancer and is suitable for diagnosis, control of therapy efficiency and follow up care of patients with nonsmall cell lung carcinoma, especially squamous cell carcinomas of the lung. TPA and TPS are two other tumour markers, which represent different cytokeratins in serum. In the present investigation we compared the presence of CYFRA 21-1, TPA and TPS in various benign diseases and their significance in lung cancer.
Patients
Two reference groups were investigated: 50 persons who were normal according to clinical examination, and showed no abnormal serum values of clinical chemical analytes; and 273 patients with various benign disorders including 58 patients with benign diseases of the lung (tuberculosis, sarcoidosis, aspergillosis, pneumonia, chronic obstruction, hamartoma), 46 with benign diseases of the gastrointestinal tract (liver cirrhosis, hepatitis, pancreatitis, primary biliary cirrhosis, colitis uicerosa, Crohn's disease), 30 women with benign disorders of the breast (mastopathia stage I, II, III, fibroadenoma, galactorrhoe), 73 patients with benign urological diseases (stones, urinary infections), 31 patients with chronic or acute renal failure and 30 patients with benign gynaecological diseases. As tumour patients we investigated the sera of 218 patients with histologically proven lung cancer (62 small cell, 67 adeno, 66 squamous cell, 17 large cell and 6 undifferenciated); all of them were collected at an active stage of disease (primary diagnosis or recurrent disease). As this study was done retrospectively, the sera were stored at -70 °C in our serum bank.
Methods
The CYFRA 21-1 concentrations were determined by using the two-step-sandwich Enzymun^-assay (Boehringer Mannheim, Germany) on the automated test system ES600. TPA values were determined with the IRMA of Sangtec Medicals (Sweden) and TPS values with the IRMA of Beki Diagnostics (Sweden). For the CEA and SCC values we used the enzyme imraimoassays on the IMx (automated test system, Abbott, USA) and for the neuron-specific enolase determinations the radioimmunoassay from Pharmacia (Sweden). Diagnostic specificity
Results

Correlation
In order to compare our results for the different tumour markers under the same conditions we followed the recommendations of the "Hamburger group for the standardization of tumour markers" (12) and fixed the cut off values for each reference group at a specificity of 95%. This basic postulation resulted in many different cut off-values (tab. 1). In 95% of the normal healthy controls, CYFRA 21-1-values were then below 1.8 μg/l, TPA-values were below 133 U/l and TPS-values were below 97 U/l. In patients with benign diseases of the lung the cut off changed to a small extent for CYFRA 21-1 (2.1 μg/l) and for TPA (131 U/l), and to a greater extent for TPS (237 U/l). In agreement with our pilot study (9) , CYFRA 21-1 showed high diagnostic sensitivity (79%) for squamous cell carcinomas of the lung (tab. 2). Corresponding values for other tests were: TPA (62%), SCC (38%), TPS (18%) and CEA (25%). This good profile of specificity and sensitivity of CYFRA 21-1 is illustred by the receiver operating characteristic curves in figure 2 . Tab 3 Sensitivity of the combinations of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA), tissue ' polypeptide specific antigen (TPS), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron specific enolase (NSE) in lung cancer at a specificity of 95% versus benign diseases of the lung. For the calculations both markers combined had to fulfil the specificity of 95% and at least one of them had to show a true positive test result. In adenocarcinomas of the lung (tab. 2) the sensitivity of CYFRA 21-1 was 54% (TPA 40%, CEA 41%, TPS 16% and SCC 5%). None of the combinations could improve this diagnostic sensitivity.
CYFRA 21-1 also showed the best specificity-sensitivity profile in large cell carcinomas of the lung, with 65% true positive test results (TPA 41%, TPS 18%, CEA 27%, SCC1%).
In small cell lung carcinomas the diagnostic sensitivity of CYFRA 21-1 was about 52%, while NSE showed a true positive test result in 55% of the cases (TPA 52%, TPS 32%, CEA 18%, SCC 6%)., This high sensitivity could be slightly increased to 62% only by combining CYFRA 21-1 with NSE.
For all non-small cell lung carcinomas the sensitivities were also calculated following tumour size and tumour stages (tab. TPA (Tl: 4%, T4: 0%) and also none for TPS (Tl: 4%, T4: 0%). CEA proved to have a good correlation (Tl: 11%, T4: 54%) and to a lower extent also SCC (Tl: 7%, T4: 36%).
TPA and TPS again proved to be independent of the extent of disease, as their sensitivities were almost the same for stage II (TPA: 55%, TPS: 23%) and stage IV (TPA: 46%, TPS 18%). The CEA-values were clearly dependent on tumour stages (stage I: 15%, stage IV: 57%), whereas the number of true positive SCC-results showed no correlation (stage I: 19%, stage IV: 22%).
Discussion
Like most the other tumour markers, cytokeratins are not organ specific and therefore can be expressed in all human tissues. We compared the expression of the "cytokeratin markers" CYFRA 21-1, TPA and TPS in various benign diseases before addressing the main question of this investigation concerning their clinical significance in lung cancer. Because we fixed the different specificities at a level of 95%, we obtained, for most of the different reference groups investigated, significantly higher cut off values than those normally used in routine laboratories (tab. 1). This fact of course results in fewer true positive test results and therefore in a lower diagnostic sensitivity. Compared with the marker values obtained for the healthy control group, the cut off values necessary for a specificity of 95% in benign diseases of the lung (tab. 1) did not clearly change for CYFRA 21-1 (2.1 μg/l) and TPA (131 U/l), but were different for TPS (237 U/l). In benign gynaecological disorders the cut off values were almost the double for all 3 markers as compared with the healthy persons. In patients with mastopathia the CYFRA 21-1 values were very low (cut off: 1.3 μg/l), whereas TPA and TPS were increased (TPA: 243 U/l, TPS: 226 U/l). Benign urological diseases only slightly influenced all markers, whereas renal failure was combined with a clear increase of CYFRA 21-1 (cut off: 7.2 μβ/l), TPA (cut off: 243 U/l) and TPS (cut off: 404 U/l), probably due to the fact that cytokeratin fragments are eliminated by the renal pathway and therefore accumulate in renal failure. The highest influence, especially on the TPA and TPS concentrations, was caused by benign disorders of the gastrointestinal tract: TPA (cut off: 713 U/l) and moreover TPS (cut off: 2021 U/l); CYFRA 21-1 showed slightly elevated levels (cut off: 5.2 μg/l).
In lung cancer, NSE, with a sensitivity of 55%, was confirmed as the marker of first choice for small cell lung carcinomas (CYFRA 21-1: 52%, TPA: 52%, TPS: 32%, CEA: 18%, SCC: 6%).
In non-small cell lung carcinomas, CYFRA 21-1 discriminated with 64% sensitivity at a 95% specificity better between benign diseases of the lung and lung carcinomas than TPA (50%), TPS (17%), CEA (33%) and SCC (19%). Moreover, as demonstrated in table 4, the sensitivity of CYFRA 21-1 correlates clearly with tumour size and tumour stage.
In adenocarcinomas of the lung, CYFRA 21-1, with 54% true positive test results, showed the highest sensitivity (also compared with the combined determinations), followed by TPA (40%) and CEA (41%). TPS (16%) and SCC (5%) showed a very small number of true positive test results.
In large cell lung carcinomas, CYFRA 21-1 revealed a sensitivity of 65% (TPA: 41%, CEA: 27%, TPS: 18%). In this case a combination of CYFRA 21-1 and TPA increased sensitivity to 77%. In squamous cell carcinomas of the lung, the benefit of CYFRA 21-1 versus the other markers became evident with 79% true positive test results (TPA: 62%, CEA: 25%, SCC: 38%, TPS: 18%). None of the possible combination could improve this good result (tab. 5).
Independent of the histological type, CYFRA 21-1 emerged as a type of "pan-marker" for lung cancer because of its high overall sensitivity of 61 % in lung cancer (TPA: 51%, CEA: 28%, TPS: 22%, SCC: 18%, NSE: 19%). From our investigations it is evident that TPA detects at least partly the same substance as CYFRA 21-1 (the sensitivities compared with the markers TPS, CEA, SCC and NSE were rather high, but not as high as for CYFRA 21-1) whereas TPS represents a completely different clinical chemical analyte (lowest number of true positive test results over the whole investigation). These findings correspond cleary to the very recent results of the comparison of the antibodies used in the CYFRA 21-1, TPA and TPS assay by immunoblotting. These investigations, presented by Bodenm ller et al. at a recent symposium on cytokeratins (5), show that TPA detects mainly cytokeratin 8 and 19 and to a very small degree cytokeratin 18. Therefore TPA gives the highest number of true positive test results after CY-FRA 21-1 (which does not detect cytokeratin 8 and 18, but only 19). TPS detects mainly cytokeratin 18 and to a small extent 8 and 19. This explains the negligible sensitivities of TPS in lung cancer.
In conclusion, CYFRA 21-1 is superior to the other cytokeratin markers, TPA and TPS, as a marker of lung cancer.
